Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Data 1 from Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research
  1. Home
  2. Publications
  3. Supplementary Data 1 from Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

Supplementary Data 1 from Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

Authors:
  • ZWZhichao Wang
    Zhichao Wang
  • JHJingxuan Huang
    Jingxuan Huang
  • JLJun Liu
    Jun Liu
  • YLYuehua Li
    Yuehua Li
  • CWChengjiang Wei
    Chengjiang Wei
  • YGYihui Gu
    Yihui Gu
  • YCYing Cheng
    Ying Cheng
  • YXYanjun Xu
    Yanjun Xu
  • HTHongqi Tian
    Hongqi Tian
  • QLQingfeng Li
    Qingfeng Li

Open Access
Publisher website
Google Scholar
  • 17 June 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/1078-0432.32711497
Abstract
No abstract available
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.